Conversely, rosiglitazone shows mixed effects, partially downregulating insulin signaling proteins (IR, IRS1 and AKT) in T2D [143], but enhancing insulin signaling ex vivo in PreDM rats [141]. The gene discussed is IRS1; the disease is type 2 diabetes mellitus.